Abstract:Meningiomas (MNs), arising from the arachnoid/meningeal layer, are nonresponsive to chemotherapies, with ∼50% showing loss of the Neurofibromatosis 2 (NF2) tumor suppressor gene. Previously, we established NF2 loss activates mechanistic target of rapamycin complex 1 (mTORC1) and mechanistic target of rapamycin complex 2 (mTORC2) signaling, leading to clinical trials for NF2 and MN. Recently our omics studies identified activated ephrin (EPH) receptor and Src family kinases upon NF2 loss. Here, we report increased expression of several ligands in NF2-null human arachnoidal cells (ACs) and the MN cell line Ben-Men-1, particularly neuregulin-1/heregulin (NRG1), and confirm increased NRG1 secretion and activation of V-ERB-B avian erythroblastic leukemia viral oncogene homolog 3 (ERBB3) receptor kinase. Conditioned-medium from NF2-null ACs or exogenous NRG1 stimulated ERBB3, EPHA2, and mTORC1/2 signaling, suggesting pathway crosstalk. NF2-null cells treated with an ERBB3-neutralizing antibody partially downregulated mTOR pathway activation but showed no effect on viability. mTORC1/2 inhibitor treatment decreased NRG1 expression and downregulated ERBB3 while re-activating pAkt T308, suggesting a mechanism independent of NRG1-ERBB3 but likely involving activation of another upstream receptor kinase. Transcriptomics after mTORC1/2 inhibition confirmed decreased ERBB3/ERBB4 while revealing increased expression of insulin-like growth factor receptor 1 (IGF1R). Drug treatment co-targeting mTORC1/2 and IGF1R/insulin receptor attenuated pAkt T308 and showed synergistic effects on viability. Our findings indicate potential autocrine signaling where NF2 loss leads to secretion/activation of NRG1-ERBB3 signaling. mTORC1/2 inhibition downregulates NRG1-ERBB3, while upregulating pAkt T308 through an adaptive response involving IGF1R/insulin receptor and co-targeting these pathways may prove effective for treatment of NF2-deficient MN.

Combined Mtor/mek Inhibition Prevents Proliferation and Induces Apoptosis in NF2-mutant Tumors

The NF2 Tumor Suppressor Merlin Interacts with Ras and RasGAP, Which May Modulate Ras Signaling

Merlin Cooperates with Neurofibromin and Spred1 to Suppress the Ras-Erk Pathway.

Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells

mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition

Tumorigenic Transformation by CPI-17 Through Inhibition of a Merlin Phosphatase.

Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2

Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis

Role of Merlin/NF2 inactivation in tumor biology

Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors

P53 Performs an Essential Role in Mediating the Oncogenic Stimulus Triggered by Loss of Expression of Neurofibromatosis Type 2 During in Vitro Tumor Progression.

Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma

The CREB-binding Protein Inhibitor ICG-001: a Promising Therapeutic Strategy in Sporadic Meningioma with NF2 Mutations.

EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma

Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma

MFN2 Suppresses Cancer Progression Through Inhibition of Mtorc2/akt Signaling.

MEK inhibition enhances the antitumor effect of radiation therapy in NF1-deficient glioblastoma

VprBP Targets Merlin to the Roc1-Cul4A-DDB1 E3 Ligase Complex for Degradation

[Treatment of Triple Negative Breast Cancer Cells with Combination of Mtor1/2 Inhibitor AZD8055 and MEK1/2 Inhibitor PD0325901].

Synergistic Effect of Nutlin-3 Combined with MG-132 on Schwannoma Cells Through Restoration of Merlin and P53 Tumour Suppressors

Combined Inhibition Of The Egfr And Mtor Pathways In Egfr Wild-Type Non-Small Cell Lung Cancer Cell Lines With Different Genetic Backgrounds